IQVIA Holdings Inc. (NYSE:IQV) Receives $249.19 Average PT from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned a consensus rating of “Moderate Buy” from the twenty-one analysts that are currently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $249.1875.

Several research analysts have recently weighed in on IQV shares. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Morgan Stanley increased their target price on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Stifel Nicolaus boosted their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. UBS Group raised their price objective on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Finally, BMO Capital Markets started coverage on shares of IQVIA in a report on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price on the stock.

IQVIA Stock Up 0.5%

IQVIA stock opened at $241.95 on Friday. The firm has a 50 day moving average price of $225.53 and a 200-day moving average price of $201.95. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a market capitalization of $41.20 billion, a P/E ratio of 33.19, a P/E/G ratio of 2.45 and a beta of 1.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the previous year, the firm posted $2.84 EPS. IQVIA’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts predict that IQVIA will post 10.84 EPS for the current year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Institutional investors and hedge funds have recently modified their holdings of the company. Dakota Wealth Management increased its holdings in IQVIA by 48.2% during the 4th quarter. Dakota Wealth Management now owns 7,180 shares of the medical research company’s stock worth $1,618,000 after acquiring an additional 2,334 shares during the period. Regatta Capital Group LLC grew its position in shares of IQVIA by 7.0% during the 4th quarter. Regatta Capital Group LLC now owns 2,424 shares of the medical research company’s stock valued at $546,000 after purchasing an additional 158 shares in the last quarter. National Wealth Management Group LLC bought a new position in shares of IQVIA in the fourth quarter worth $755,000. Czech National Bank raised its position in shares of IQVIA by 4.0% in the fourth quarter. Czech National Bank now owns 44,905 shares of the medical research company’s stock worth $10,122,000 after buying an additional 1,729 shares in the last quarter. Finally, Thrive Wealth Management LLC bought a new stake in IQVIA during the fourth quarter valued at $218,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.